Abstract
Overview
Introduction
Non-Hodgkin' s lymphoma (NHL) is the most common hematological malignancy and
is comprised of around 30 different disease subtypes. Each of these present
with a distinct set histological, genetic and clinical characteristics.
Treatment options in NHL include chemotherapy, targeted therapies, stem cell
transplantation and radiotherapy.
Scope
- NHL background and epidemiology, including forecast incidence of the major
subtypes in the seven major markets
- Treatment of NHL by subtype and line of therapy, including major treatment
controversies and areas of unmet need
- Examination of pipeline activity including profiles of late-phase pipeline
drugs
- Stakeholder opinions based on qualitative interviews with opinion leaders
from the US and Europe
Highlights
Rituxan-based regimens constitute the mainstay of first-line treatment options
in several NHL subtypes. Uptake of Rituxan in the maintenance setting for
follicular lymphoma (FL) has allowed the drug to achieve further market
penetration.
There is a lack of consensus over the treatment of relapsed and refractory
disease in most NHL subtypes. Refractory patients are poorly served by
currently available treatment options. Other unmet needs include detection of
patients with aggressive lymphoma at high risk of relapse and an efficacious
maintenance therapy for these patients.
The NHL late-phase pipeline is relatively active, with 10 Phase IIII drugs and
46 Phase II drugs. Monoclonal antibodies are among those agents that continue
to demonstrate promising signs of clinical and commercial potential. However,
Rituxan' s status as market leader is unlikely to be challenged within the next
510 years.
Reasons to Purchase
- Understand current epidemiological trends in non-Hodgkin' s lymphoma and
ongoing treatment options
- Identify limitations of therapy currently available to non-Hodgkin' s
lymphoma patients and the potential of future therapy
- Identify the key products in late-phase development for NHL. Consider,
assess and react to opportunities and risks influencing their future potential
View Cart
